Corton Capital Inc. Grows Position in NeuroPace, Inc. $NPCE

Corton Capital Inc. boosted its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 47.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,341 shares of the company’s stock after purchasing an additional 7,817 shares during the period. Corton Capital Inc. owned approximately 0.07% of NeuroPace worth $271,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of NeuroPace by 15.2% during the 1st quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock worth $212,000 after buying an additional 2,267 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in NeuroPace by 7.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company’s stock valued at $482,000 after acquiring an additional 2,700 shares during the period. Birchview Capital LP increased its stake in NeuroPace by 64.4% during the first quarter. Birchview Capital LP now owns 16,442 shares of the company’s stock worth $202,000 after acquiring an additional 6,442 shares during the last quarter. AlphaQuest LLC purchased a new position in shares of NeuroPace in the 2nd quarter worth about $82,000. Finally, Calamos Advisors LLC purchased a new position in shares of NeuroPace in the 1st quarter worth about $136,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Stock Performance

NeuroPace stock opened at $9.40 on Tuesday. The firm has a market capitalization of $310.95 million, a PE ratio of -11.19 and a beta of 1.90. NeuroPace, Inc. has a one year low of $6.03 and a one year high of $18.98. The stock’s 50 day moving average price is $10.12 and its 200 day moving average price is $10.84. The company has a debt-to-equity ratio of 3.02, a quick ratio of 4.51 and a current ratio of 5.47.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The firm had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NPCE has been the subject of a number of research reports. Zacks Research cut NeuroPace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company dropped their price objective on shares of NeuroPace from $17.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.